May 14, 2015 / 6:32 AM / 3 years ago

BRIEF-Hikma reiterates 2015 forecast

May 14 (Reuters) - Hikma Pharmaceuticals Plc :

* On reported basis, expect full-year group revenue growth of around 2 pct, reflecting foreign exchange rate movements in year to date

* Made good start to year and very pleased to reiterate guidance for 2015

* Expect adjusted operating margin of around 35 pct for injectables unit

* Continue to expect sales from recent product launches to accelerate in second half, and therefore reiterate guidance for full year generics revenue of around $200 million

* Remain on track to sustain 2015 global injectables revenue at same level as 2014 for both half year and full year

* Continue to expect full-year group revenue growth of around 6 pct in constant currency

* For first half, expect group revenue in constant currency to be broadly in line with same period last year

* Continue to expect full-year branded revenue growth in low teens and improvement in adjusted operating margin of around 200 basis points on constant currency Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below